Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Chemotherapy-Induced Anemia Market Spotlight Report 2019: Pfizer’s Epogen Biosimilar Retacrit Launches at 33% Off in a US Market where Amgen’s Already Competitive - ResearchAndMarkets.com

December 2, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Dec 2, 2019--

The “Market Spotlight: Chemotherapy-Induced Anemia” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The proportions of CIA and the severity of anemia vary by region, cancer type, and stage.
  • All of the approved drugs for CIA target the erythropoietin receptor. These drugs are all administered via both the intravenous and subcutaneous routes.
  • There are only two industry-sponsored drugs in active clinical development for CIA, both of which are in Phase III. Therapies in development for CIA focus on targets such as iron and hypoxia-inducible factor-prolyl hydroxylase (HIF-PH). These drugs are administered via the intravenous and oral routes.
  • The only high-impact upcoming event in the CIA space is topline Phase III trial results for roxadustat. The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 18.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 9.3 years in the overall hematology space.
  • There have been only two licensing and asset acquisition deals involving CIA drugs during 2014-19. The values of the deals have not been disclosed.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III-IV, and 39% in Phase I-II.
  • Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 67 trials.
  • Amgen leads industry sponsors with the highest number of clinical trials for CIA, followed by Johnson & Johnson.

Key Topics Covered:

1. Overview

2. Key Takeaways

3. Disease Background

  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis

4. Treatment

  • Iron supplements
  • Blood transfusion
  • Erythropoietin-stimulating agents (ESAs)

5. Epidemiology

6. Marketed Drugs

7. Pipeline Drugs

8. Key Upcoming Events

9. Key Regulatory Events

  • Pfizer’s Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen’s Already Competitive

10. Probability of Success

11. Licensing and Asset Acquisition Deals

12. Revenue Opportunity

13. Clinical Trial Landscape

  • Sponsors by status
  • Sponsors by phase

14. Bibliography

Companies Mentioned

  • Amgen
  • Johnson & Johnson

For more information about this report visit https://www.researchandmarkets.com/r/eh189l

View source version on businesswire.com:https://www.businesswire.com/news/home/20191202005828/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 12/02/2019 01:34 PM/DISC: 12/02/2019 01:34 PM